Epizyme Inc  

(Public, NASDAQ:EPZM)   Watch this stock  
Find more results for EPZM
10.50
-0.90 (-7.89%)
After Hours: 10.50 0.00 (0.00%)
Jan 17, 4:40PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.30 - 11.25
52 week 7.02 - 13.46
Open 11.25
Vol / Avg. 412,072.00/334,055.00
Mkt cap 609.12M
P/E     -
Div/yield     -
EPS -1.85
Shares 58.01M
Beta 2.28
Inst. own 95%
Mar 7, 2017
Q4 2016 Epizyme Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 9, 2017
Epizyme Inc at JPMorgan Healthcare Conference
Nov 3, 2016
Q3 2016 Epizyme Inc Earnings Release
Nov 3, 2016
Q3 2016 Epizyme Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -369.62% -5170.94%
Operating margin -377.07% -5177.69%
EBITD margin - -5122.27%
Return on average assets -33.67% -63.47%
Return on average equity -39.93% -80.27%
Employees 89 -
CDP Score - -

Address

400 Technology Sq Ste 4
CAMBRIDGE, MA 02139-3584
United States - Map
+1-617-2295872 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Officers and directors

Robert H. Bazemore Jr. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Andrew E. Singer Executive Vice President, Finance and Administration, Chief Financial Officer, and Treasurer
Age: 45
Bio & Compensation  - Reuters
Matthew Ros Chief Operating Officer
Bio & Compensation  - Reuters
Robert A. Copeland Ph.D. Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Pamela Strode Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters
Michael Boretti Ph.D. Vice President - Business Development
Bio & Compensation  - Reuters
Susan E. Graf Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Peter Ho M.D., Ph.D. Chief Development Officer
Age: 53
Bio & Compensation  - Reuters
Andrew R. Allen M.D. Ph.D. Director
Age: 49
Bio & Compensation  - Reuters
Robert J. Gould Ph.D. Director
Age: 60
Bio & Compensation  - Reuters